Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

CG Oncology (CGON) Non Operating Income (2023 - 2025)

CG Oncology (CGON) has disclosed Non Operating Income for 3 consecutive years, with -$22.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Non Operating Income fell 10.64% year-over-year to -$22.5 million, compared with a TTM value of -$152000.0 through Dec 2025, down 5166.67%, and an annual FY2025 reading of -$152000.0, down 5166.67% over the prior year.
  • Non Operating Income was -$22.5 million for Q4 2025 at CG Oncology, down from $7.3 million in the prior quarter.
  • Across five years, Non Operating Income topped out at $7.9 million in Q3 2024 and bottomed at -$22.5 million in Q4 2025.
  • Average Non Operating Income over 3 years is $557750.0, with a median of $6.2 million recorded in 2023.
  • Peak annual rise in Non Operating Income hit 69087.5% in 2024, while the deepest fall reached 395.26% in 2024.
  • Year by year, Non Operating Income stood at $6.9 million in 2023, then plummeted by 395.26% to -$20.4 million in 2024, then dropped by 10.64% to -$22.5 million in 2025.
  • Business Quant data shows Non Operating Income for CGON at -$22.5 million in Q4 2025, $7.3 million in Q3 2025, and $7.3 million in Q2 2025.